| Name | Title | Contact Details |
|---|
Medical Mobility, Inc. is a Goodlettsville, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ContourMD is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Assure Neuromonitoring is a Colorado-based company that works with neurosurgeons and orthopedic spine surgeons to provide a turnkey suite of services that support intraoperative neuromonitoring activities during invasive surgeries. Assure employs its own staff of technologists and uses its own state-of-the-art monitoring equipment, handles 100% of intraoperative neuromonitoring scheduling and setup, and bills for all technical services provided. While Assure focuses primarily on supporting spinal and vascular surgeries, plans are in place to support other classes of medicine that rely on the standard of care that intraoperative neuromonitoring provides. Assure Neuromonitoring is accredited by The Joint Commission and committed to delivering the highest quality service in the industry. Our patient driven focus is at the core of our organization and is impressed upon all stakeholders. Assure employs the highest quality technologists and support staff in the field, thus instilling continuity, reliability and confidence for both patients and physicians alike.
Velano Vascular aims to improve the hospital experience by reducing the pain, anxiety, and inefficiencies of blood draws.
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.